Ecuador

ecuador-small.jpgEcuador is a dynamic and growing market, driven by government investment and strong oil and mining industries. The country’s GDP totaled more than $70 billion in 2012 while pharmaceutical sales have amounted to $1.27 billion and continue to grow.

However, the pharmaceutical market is still small compared to global standards. As BMI stated: “The major disincentive for multinational drugmakers to launch their products in Ecuador is the limited size of the pharmaceutical market, the preference for affordable generic drugs, low prevalence of chronic diseases, and a weak business environment. However, foreign generic drugmakers can seek to increase their presence in the country's drug market as it relies heavily on imported medicines.”

Major drug companies with presence in Latin America have recognised Ecuador’s significant growth potential. In 2013, Japanese drug major Takeda Pharmaceuticals International GmbH (TYO: 4502) announced further expansion of Latin America branches with the launch of its wholly-owned subsidiary in Ecuador. Takeda Ecuador S.A. will be headquartered in Quito and will be responsible for the sales and marketing of Takeda’s products in Ecuador.

  • <<
  • 1
  • >>

1 to 2 of 2 results

Ecuador News

  • Increasing investment in Latin American pharma market

    Increasing investment in Latin American pharma market

    12-02-2014

    Around $12.7 billion has been invested in Latin America’s pharmaceutical market through mergers and acquisitions in recent years, and with untapped potential identified in countries across the region, companies are expected to seize upon further opportunities to drive future growth.

  • Ecuador HIV Blood Scandal: Arrests

    Ecuador HIV Blood Scandal: Arrests

    09-09-1996

    Four people including a hospital director have been arrested in Ecuador in connection with the HIV contamination of 21 hemodialysis...

  • <<
  • 1
  • >>

1 to 2 of 2 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top